Similar articles

• A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions.

  Mittal S, Watson HG. Mittal S, et al. Br J Haematol. 2006 May;133(4):355-63. doi: 10.1111/j.1365-2141.2006.06023.x. Br J Haematol. 2006. PMID: 16643441 Review.
• Recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.

  Manning BJ, Hynes N, Courtney DF, Sultan S. Manning BJ, et al. Eur J Vasc Endovasc Surg. 2005 Nov;30(5):525-7. doi: 10.1016/j.ejvs.2005.06.021. Eur J Vasc Endovasc Surg. 2005. PMID: 16099693
• [Administration of activated recombinant factor VII (novo seven) for the control of massive bleeding in gynecology].

  Tanchev S, Pandurski F, Georgiev A, Gesheva Iu, Platikanov V, Dinov P. Tanchev S, et al. Akush Ginekol (Sofiia). 2004;43 Suppl 2:32-5. Akush Ginekol (Sofiia). 2004. PMID: 15518274 Bulgarian.
• Use of recombinant factor VIIa for adjunctive hemorrhage control in trauma and surgical patients.

  Benharash P, Bongard F, Putnam B. Benharash P, et al. Am Surg. 2005 Sep;71(9):776-80. doi: 10.1177/000313480507100917. Am Surg. 2005. PMID: 16468517
• Recombinant factor VIIa in the treatment of bleeding.

  Midathada MV, Mehta P, Waner M, Fink LM. Midathada MV, et al. Am J Clin Pathol. 2004 Jan;121(1):124-37. doi: 10.1309/D0G0-C96V-05CJ-5B4J. Am J Clin Pathol. 2004. PMID: 14750250 Review.